On June 10, 2021, we participated to the #ECFS2021 virtual conference, proposing a symposium during which results from new studies related to Simeox therapy in CF were presented:
- Pr Dorota Sands, head of the CF department of the Institute of Mother and Child near Warsaw (POLAND), presented for the first time results of the homecare Simeox trial in Pediatric Cystic Fibrosis patients
- Dr Dorit Fabricius and Dr Hanna Schmidt from CF center of Ulm (GERMANY) presented the results of their pilot study about short term effects of Simeox therapy, including innovative methods to assess the Simeox therapy
- Finally, Laurent Morin, Medical Affairs Director at PhysioAssist, presented the main outcomes from the 3 European virtual roundtables about "Simeox therapy at each stage of the CF patient care” that were held in May 2021.

This session has driven high interest from the conference delegates from all over the world!
We are pleased to open publically the content of this session. (Re)watch to learn more about those new insights on #simeox therapy in CF!

#ECFS2021 #Simeox #Cysticfibrosis

Simeox is a class 2a medical device, intended for use in healthcare institutions, medical or paramedical practices, and at home. Before use, carefully read the user manual supplied with the medical device. This medical device is a regulated healthcare product that carries the CE marking under this regulation.

свернуть